| Database ID | Agent | Target | Cancer Type | Detail |
| DB00661 | ipilimumab | Cytotoxic Tlymphocyte antigen 4 (CTLA4) | melanoma | view |
| DB00662 | sunitinib | FL cytokine receptor
Mast/stem cell growth factor receptor
Vascular endothelial growth factor receptor 2
Plateletderived growth factor receptor | neuroendocrine tumour | view |
| DB00663 | everolimus | Serine/threonineprotein kinase mTOR | pancreatic cancer | view |
| DB00664 | bevacizumab | Vascular endothelial growth factor | pancreatic cancer | view |
| DB00665 | erlotinib, cixutumumab | NA | pancreatic cancer | view |
| DB00666 | bevacizumab and erlotinib | NA | pancreatic cancer | view |
| DB00667 | sorafenib and erlotinib | NA | pancreatic cancer | view |
| DB00668 | nimotuzumab | Epidermal growth factor receptor | pancreatic cancer | view |
| DB00669 | pazopanib | Plateletderived growth factor receptor
Mast/stem cell growth factor receptor
Vascular endothelial growth factor receptor 2 | neuroendocrine tumour | view |
| DB00670 | sorafenib | Vascular endothelial growth factor receptor 1
BRaf protooncogene serine/threonineprotein kinase
Protooncogene tyrosineprotein kinase receptor ret | pancreatic cancer | view |
| DB00671 | everolimus, cetuximab | NA | pancreatic cancer | view |
| DB00672 | bevacizumab and erlotinib | NA | pancreatic cancer | view |
| DB00673 | erlotinib | Epidermal growth factor receptor | pancreatic cancer | view |
| DB00674 | gefitinib | Epidermal growth factor receptor | pancreatic cancer | view |
| DB00675 | cetuximab | Epidermal growth factor receptor | pancreatic cancer | view |